⚠ Evidence warning: Clinical trials or other evidence do not support the claim that chaga cures or prevents cancer, including the folk report that chaga-drinking villages had less stomach cancer. This page keeps it as a report of what people, websites or other media say.
Chaga Mushroom Cancer Research
Honest framing first. Chaga (Inonotus obliquus) is not a cancer treatment. The widely circulated claim that chaga "cures cancer" — whether traced to Aleksandr Solzhenitsyn's 1968 novel Cancer Ward, to Russian folk-medical tradition, or to internet supplement marketing — is not supported by clinical evidence. What is supported: betulinic acid (a triterpenoid that chaga extracts from its birch host) induces apoptosis in several tumor cell lines in vitro, crude chaga extracts inhibit tumor growth in mouse tumor models, and a low gastric-cancer rate reported by tradition in birch-rich rural Russian villages may reflect a real (but currently unverifiable) traditional-diet contribution. What is missing: any rigorous randomized controlled trial in human cancer patients. This deep-dive walks through the historical context, the actual cell-culture and animal data, the proposed mechanisms (betulinic acid apoptosis induction, immunomodulatory anti-tumor activity, antioxidant cancer prevention), and what is known about chaga alongside cancer care.
Table of Contents
- Solzhenitsyn's Cancer Ward and the Russian Folk-Cancer Story
- The Russian Village Gastric-Cancer Observation
- A Licensed Russian Chaga Extract — The Russian Drug Listing
- Betulinic Acid Apoptosis Mechanism (In Vitro)
- Tumor Cell Line Data (Melanoma, Colon, Liver, Breast)
- Mouse Tumour Studies and Crude Extract Data
- The Immunomodulatory Anti-Tumor Pathway
- The State of Human Evidence (Honest Assessment)
- The Memorial Sloan Kettering Position and Why It Matters
- What Is Known About Chaga Alongside Cancer Care
- Key Research Papers
- Connections
- Featured Videos
Solzhenitsyn's Cancer Ward and the Russian Folk-Cancer Story
Aleksandr Solzhenitsyn's semi-autobiographical 1968 novel Cancer Ward (Rakovyy Korpus) drew on his own experience as a Soviet labor-camp survivor with cancer who, in 1954, was treated in a hospital in Tashkent, where his tumor went into remission. In one of the novel's recurring threads, characters discuss a peasant remedy from a Russian village — a black mushroom brewed as tea (chai chaga) — and the rumor circulating in the cancer ward that the peasant doctor "Maslennikov" has cured tumors in his rural practice with this remedy.
Solzhenitsyn's text is a literary device, not a medical claim, but the framing carried enormous weight. Cancer Ward was internationally famous; Solzhenitsyn received the 1970 Nobel Prize in Literature “for the ethical force with which he has pursued the indispensable traditions of Russian literature”, and the novel was widely read in the West at exactly the moment of growing Western interest in plant-derived cancer treatments (the early vinca alkaloid and taxane discoveries were happening in the same decade). The novel inspired the first wave of Western interest in chaga and the first wave of Soviet-era scientific investigation under Bulatov, Shashkina, and Yefimov at the Komarov Botanical Institute in Leningrad.
Two important caveats on the literary source:
- The "Maslennikov" peasant doctor character is fictional, though Solzhenitsyn based him loosely on real folk-medical practitioners he had heard about.
- Solzhenitsyn's own cancer went into remission after hospital treatment in Tashkent in 1954; that hospital experience, not a chaga cure, is what the novel draws on.
The fair reading is that Solzhenitsyn dramatized a real folk-medical tradition that had genuine cultural and historical roots, but the literary framing was not a medical endorsement, and the subsequent Western marketing claims that conflate the novel with clinical evidence are not justified.
The Russian Village Gastric-Cancer Observation
The substrate observation that gave rise to the Russian chaga tradition is genuinely interesting and harder to dismiss than the novel-derived claims. Rural birch-forest regions of Russia (the Komi-Permyak republic, parts of Karelia, parts of Western Siberia) are reported in the folk tradition to have had anomalously low gastric and stomach cancer rates compared to nearby urban or non-birch-region populations. No published registry data measuring or confirming this difference were found.
Three plausible explanations:
- Chaga consumption is genuinely protective — the strongest version of the traditional claim. Biologically plausible via the immunomodulatory and antioxidant mechanisms, but never confirmed by intervention trial.
- Confounding by lifestyle and environment — rural birch-forest populations differ from urban populations in many ways: lower processed-food intake, less industrial pollution, more physical activity, lower nitrosamine exposure (a known gastric carcinogen) from less industrial food processing. Any of these could account for the gastric cancer difference without chaga playing any role.
- Reporting and diagnostic differences — rural populations had less access to medical care, so gastric cancers may have been under-diagnosed in life and under-registered at death. This would deflate apparent rates without any actual protective effect.
Modern epidemiology has not been able to disentangle these explanations because the relevant Soviet-era records are incomplete, the populations have substantially urbanized since the 1970s, and a prospective trial of chaga consumption for gastric cancer prevention is not ethically or logistically feasible. The observation is reported, but neither its size nor its cause is established.
For more on gastric cancer epidemiology and risk factors, see our Gastroenterology category page.
A Licensed Russian Chaga Extract — The Russian Drug Listing
One concrete product of the Soviet-era chaga research is a licensed Russian chaga extract — a standardized aqueous extract of Inonotus obliquus formulated with small amounts of cobalt salts (its current label lists cobalt chloride/cobalt sulfate), approved as an over-the-counter pharmaceutical in the Soviet Union (and subsequently the Russian Federation). Its label lists sluggish (hypotonic) movement of the digestive tract, stomach and duodenal ulcer and chronic gastritis, as well as weakness (asthenic states), wasting (cachexia), the period after surgery and long-term immunosuppressive therapy. It remains available in Russian pharmacies today, sold without a prescription.
The label is more conservative than the surrounding folk-medical claims would suggest. Cancer is not among its indications; its special instructions say only that it may be used as part of combination therapy for tumour diseases “to improve blood formation and digestion”. The weakness and wasting indications are the closest the label comes to the folk-medical broader claim.
The extract's clinical track record (such as it is, mostly Russian-language and not subjected to Western regulatory standards) suggests reasonable safety in adult outpatient use at recommended doses over months. The Russian pharmacopeia listing is not equivalent to U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval and does not constitute Western clinical-trial-grade evidence, but it does represent the institutional translation of the folk tradition into a regulated pharmaceutical form for a narrow indication.
Betulinic Acid Apoptosis Mechanism (In Vitro)
The most-studied anti-cancer mechanism for chaga is the activity of betulinic acid, a pentacyclic triterpenoid that chaga extracts from its birch host tree. Betulinic acid was identified as a melanoma-selective cytotoxic agent in a landmark 1995 Nature Medicine paper by Pisha and colleagues, working through bioassay-guided fractionation of plant material. Betulinic acid emerged as the active compound — tested as the purified compound, which the authors describe as “inexpensive and available in abundant supply from common natural sources, notably the bark of white birch trees”; in follow-up work in athymic mice carrying human melanoma xenografts, tumor growth was completely inhibited without observed toxicity. That mouse result is the strongest in vivo signal in this entire literature — but it is a result for purified betulinic acid given to mice, not for chaga tea drunk by people.
The proposed apoptosis mechanism involves several molecular events:
- Mitochondrial membrane permeabilization — betulinic acid acts directly on mitochondria of tumor cells, inducing the mitochondrial permeability transition pore opening, releasing cytochrome c into the cytosol, and triggering the intrinsic apoptosis pathway through the caspase-9/caspase-3 cascade.
- P53 independence — importantly, the betulinic acid apoptosis mechanism does not require functional p53, which means it can theoretically target tumor cells that have lost p53 function (a common cancer-driver mutation that confers resistance to many conventional chemotherapy drugs).
- BCL-2 family modulation — betulinic acid downregulates anti-apoptotic BCL-2 and upregulates pro-apoptotic BAX, shifting the apoptotic balance toward cell death.
- NF-kappa-B inhibition — betulinic acid inhibits NF-kappa-B activation in chronically inflamed tumor microenvironments, which can sensitize tumor cells to apoptosis induction.
- Topoisomerase inhibition — some studies show betulinic acid inhibits topoisomerase I and II, the same molecular targets as the chemotherapy drugs irinotecan and etoposide.
These in-vitro mechanisms are biologically real and have been replicated in multiple independent laboratories. The complication is that betulinic acid is poorly bioavailable orally (most of an oral dose is not absorbed) and the in-vitro effective concentrations (micromolar range) are difficult to achieve in vivo from realistic chaga consumption. No human trial of betulinic acid in cancer was found; the human trials of betulinic-acid derivatives that were found lie outside cancer, for example a phase I and II study of bevirimat, a betulinic-acid derivative, against human immunodeficiency virus (HIV) infection.
Tumor Cell Line Data (Melanoma, Colon, Liver, Breast)
Beyond the original melanoma findings, betulinic acid and crude chaga extracts have been tested against a wide range of human tumor cell lines, with reasonably consistent in-vitro cytotoxicity:
- Melanoma — original Pisha 1995 finding, replicated in multiple labs. Betulinic acid IC50 in the 1-5 microgram/mL range against MEL-1, MEL-2, MEL-3, MEL-4 melanoma lines, with minimal toxicity to normal melanocytes at the same concentrations.
- Colorectal cancer — HCT-116, HT-29, and SW-480 colorectal cell lines all show dose-dependent growth inhibition and apoptosis induction from crude chaga ethanolic extract and from purified betulinic acid.
- Hepatocellular carcinoma (liver cancer) — HepG2 and Hep3B liver cancer cell lines show apoptosis induction from chaga extracts, with mechanistic studies confirming the mitochondrial-pathway involvement.
- Breast cancer — MCF-7 (estrogen-receptor-positive) and MDA-MB-231 (triple-negative) breast cancer cell lines show growth inhibition from chaga extracts, with the triple-negative line generally more sensitive.
- Cervical cancer — HeLa cells show classical apoptosis induction by chaga extracts at concentrations of 10-50 microgram/mL.
- Glioma (brain cancer) — U87 and U251 glioma cell lines show dose-dependent growth inhibition by betulinic acid; the blood-brain barrier penetration in vivo is a separate question.
- Leukemia — K562 chronic myelogenous leukemia and HL-60 acute myelogenous leukemia cell lines show apoptosis induction from chaga extracts and from purified betulinic acid.
The breadth of in-vitro cytotoxicity is impressive and suggests that the betulinic acid mechanism (mitochondrial-pathway apoptosis induction in a p53-independent manner) is genuinely broad-spectrum. The in-vivo translation is the harder question.
Mouse Tumour Studies and Crude Extract Data
Mouse tumour studies — xenografts (where human tumor cells are implanted in immunocompromised mice and the tumor growth is tracked over weeks of treatment) and mouse tumours grown in ordinary mice — bridge the gap between cell-culture work and human clinical trials. Several have tested crude chaga extracts and purified compounds:
- Pisha 1995 — the one unambiguous animal result. Purified betulinic acid in athymic mice bearing human melanoma xenografts completely inhibited tumor growth without observed toxicity. This is purified compound, not chaga.
- Arata 2016 — continuous intake of chaga aqueous extract slowed tumor progression and maintained body temperature in tumor-bearing mice. The mice carried Lewis lung carcinoma, a mouse tumour (not a human xenograft), and drank the extract for 3 weeks at 6 mg/kg/day, a dose the authors say corresponded to that ingested daily with chaga infusion in Japan. Tumors were reduced by 60%, and in the metastasis model the number of nodules fell by 25% compared with controls. This is the closest thing to an oral whole-extract animal study, and it is a mouse study.
- Fan 2012 — a purified water-soluble chaga polysaccharide (ISP2a) showed antitumor and immunomodulatory activity in a murine tumor model: it slowed tumor growth, significantly enhanced the immune response of the tumor-bearing mice, and increased lymphocyte proliferation and production of tumor necrosis factor-α (TNF-α), consistent with the beta-glucan immune mechanism rather than direct cytotoxicity.
Three studies frequently cited in this section do not belong in it, and the correction matters. Lemieszek et al. (2011) is titled “in vitro studies” and contains no animal data at all — any tumor-volume percentage attributed to it is not in the paper. Burczyk et al. (1996) tested aqueous chaga extract on HeLa cervical cancer cells in culture, not in mice; there is no Ehrlich ascites experiment in it. Sun et al. (2008) measured blood glucose and lipid peroxidation in alloxan-diabetic mice and reports no tumor endpoint whatsoever. We have removed those three claims rather than repeat them, because in-vitro results dressed as in-vivo results are exactly how a modest mechanism becomes a marketing claim.
The honest interpretation of what animal data do exist: oral chaga extract inhibited tumor growth in mice — a 60% tumor reduction in the one oral whole-extract study (Arata 2016). That is a single study of a mouse tumour in mice, not a result in people. It is consistent with the multifaceted, low-affinity mechanism (beta-glucan immunomodulation plus betulinic acid apoptosis induction plus polyphenol antioxidant/Nrf2 signaling) and is not consistent with the marketing-claim level of "cancer treatment."
The Immunomodulatory Anti-Tumor Pathway
Beyond direct betulinic-acid cytotoxicity, chaga's anti-tumor potential operates through immunomodulation — activation of natural killer (NK) cells, tumor-associated macrophages, and cytotoxic T cells that recognize and kill tumor cells. This is the same mechanism that has been clinically successful for other medicinal mushroom polysaccharide preparations:
- PSK (polysaccharide-K from Turkey Tail mushroom) — approved in Japan as an adjuvant cancer therapy since 1977. Trials and meta-analyses from the 1980s and 1990s reported improved survival when PSK was added to chemotherapy in gastric and colorectal cancer, and the mechanism is immunomodulatory rather than directly cytotoxic. In a 1994 Lancet trial of 262 patients after curative stomach-cancer surgery, adding PSK to chemotherapy gave a 5-year survival of 73.0% versus 60.0% (p = 0.044). In a 2004 colorectal-cancer trial, PSK was taken by mouth — 3 g a day with the oral chemotherapy tegafur/uracil for 2 years — and 5-year disease-free survival was 73.0% with PSK versus 58.8% without (P=0.016). A 2006 pooled analysis of 1,094 colorectal-cancer patients in three trials found an overall survival risk ratio of 0.71 and a disease-free survival risk ratio of 0.72. Modern randomized trials have not sustained that picture. The MCSGO-CCTG phase III trial (Miyake 2018, 357 patients) found that adding PSK instead of leucovorin was not non-inferior: 3-year disease-free survival was 72.1% with PSK versus 82.3% without, and 3-year overall survival 90.7% versus 95.4%. A 2024 randomized trial found no significant disease-free survival difference either way. PSK is therefore a weaker precedent than it is usually made to sound. See our Turkey Tail Mushroom page for more detail.
- Lentinan (from Shiitake mushroom) — intravenous adjuvant cancer therapy in Japan, with similar mechanism and modest survival benefit when added to chemotherapy in gastric and lung cancer.
- Schizophyllan (from Schizophyllum commune) — intravenous adjuvant for cervical and head/neck cancer in Japan.
The mechanistic basis for these clinically successful mushroom polysaccharides is the same beta-glucan binding to Dectin-1, TLR-2/4, and complement receptor 3 that we discussed in the Immune Modulation deep-dive. The resulting natural killer cell activation, macrophage activation, and T-cell priming can contribute to anti-tumor surveillance.
Whether oral chaga consumption achieves clinically meaningful immune activation is the harder question. Lentinan is given intravenously; PSK is a purified, standardised polysaccharide taken by mouth, at 3 g a day in the colorectal trials. Oral consumption of variable wild-harvested chaga is an entirely different exposure profile.
So the analogy with clinically successful mushroom-derived cancer adjuvants is genuine but limited. Chaga's biologically plausible immune mechanism does not automatically translate to "chaga has the same effect as PSK" in clinical oncology.
The State of Human Evidence (Honest Assessment)
What we have:
- The traditional Russian report (low gastric cancer in birch-forest villages) — not measured in any published registry found, and possibly confounded.
- The licensed Russian chaga extract's label for chronic gastritis and ulcer — a regulatory adjunct indication, not a cancer treatment.
- Small case series and uncontrolled observational reports of chaga use in cancer patients with mixed outcomes — low evidence quality.
- Najafzadeh et al. (2007) took blood from 20 inflammatory-bowel-disease patients and 20 healthy volunteers and added chaga extract to the lymphocytes in the test tube, reporting a 54.9% reduction in hydrogen-peroxide-induced DNA damage. Nobody in that study swallowed any chaga. It is an ex-vivo laboratory result, not a clinical trial and not a pilot of chaga treatment.
- Human trials of betulinic-acid derivatives outside cancer, such as bevirimat against HIV infection — these are about a purified compound, not chaga, and no cancer trial of betulinic acid was found.
What we do not have:
- Any randomized controlled trial of oral chaga consumption in cancer patients with survival or progression-free survival endpoints.
- Any rigorous prospective epidemiologic study correlating chaga consumption with cancer incidence in human populations.
- Any standardized dosing recommendation that has been validated in human clinical trials.
- Any approved indication in any Western regulatory framework (U.S. Food and Drug Administration, European Medicines Agency, Health Canada, Australia's Therapeutic Goods Administration (TGA)) for chaga in oncology.
The intellectually honest position is that chaga has biologically plausible anti-tumor mechanisms supported by in-vitro and animal data, but the human evidence is preliminary and does not support specific clinical claims. In the context of cancer, the evidence supports describing chaga as a traditional adjunct with a plausible biological basis, not as an evidence-based cancer treatment.
For broader context on cancer treatment and prevention, see our Cancer page.
The Memorial Sloan Kettering Position and Why It Matters
Memorial Sloan Kettering Cancer Center (MSKCC) maintains a public herb-drug interaction database (the "About Herbs" project) that is widely consulted by oncology professionals. Their chaga entry is worth quoting because it represents the institutional position of one of the most respected cancer centers in the world:
MSKCC's chaga summary lists antitumor and other effects seen in preclinical studies, notes its use as a folk remedy in Russia and other northern European countries “to treat various ailments and diseases including cancer”, and states: “But the safety and efficacy of chaga have yet to be evaluated in clinical studies.” It lists these safety points:
- Blood-sugar drugs: in vitro, chaga had additive effects in lowering blood sugar levels; MSKCC states that the clinical significance is yet unknown (also discussed in the Adaptogenic Effects deep-dive).
- The bleeding risk from chaga's anti-platelet activity: chaga extract inhibited platelet aggregation in a mouse model and may have synergistic effects with anticoagulant or antiplatelet drugs, though MSKCC states the clinical relevance is not known. Its patient section says chaga mushroom may increase the risk of bleeding.
- Oxalate kidney damage (oxalate nephropathy): a 72-year-old Japanese woman with liver cancer who took 4-5 teaspoons of chaga powder a day for 6 months needed hemodialysis, and her kidney function did not recover. MSKCC also lists a 69-year-old man who took 10-15 g of chaga powder a day with 500 mg of vitamin C a day for 3 months, and a 49-year-old man with end-stage kidney disease after long-term chaga use for atopic dermatitis.
The second kidney case is described in a 2020 Korean report: the 49-year-old man had taken chaga powder for years for severe (intractable) atopic dermatitis, and his kidney biopsy showed oxalate crystal deposits. The leftover chaga measured “14.2/100 g” oxalate, and his estimated daily oxalate intake was 2 times that of a usual diet for four years and 5 times for one year.
The MSKCC summary is representative of what mainstream Western oncology says about chaga: biologically plausible, traditionally used, not yet evaluated in clinical studies, and with several documented safety concerns. Its patient section asks people to tell their healthcare providers about any dietary supplements they take, because “This will help them manage your care and keep you safe.”
What Is Known About Chaga Alongside Cancer Care
What the sources above report for people with cancer who use chaga:
- Disclosure to the care team. MSKCC's patient guidance asks people to tell their healthcare providers about any dietary supplements they take, so the team can manage their care; chaga's effects on platelets and blood sugar in laboratory studies bear on bleeding and glucose results.
- Chaga is not a substitute for conventional treatment. No human trial shows that chaga treats cancer. The biggest harm associated with traditional cancer remedies is not direct toxicity but rather delay or refusal of effective conventional treatment.
- Surgery and bleeding. The anti-platelet effect of chaga can increase perioperative bleeding: chaga extract inhibited platelet aggregation in a mouse model, and MSKCC's patient page says chaga mushroom may increase the risk of bleeding.
- Chemotherapy. No formal study of interactions between chaga and chemotherapy drugs was found, and the multifactorial chaga mechanism makes prediction difficult, so any interaction is unknown.
- Transplant recipients and immunosuppressants. The immune-activating effect seen in laboratory studies raises a theoretical concern for organ-transplant recipients and people on immunosuppressant drugs; no interaction study was found.
- Blood sugar. In vitro, chaga had additive effects in lowering blood sugar; MSKCC states that the clinical significance is yet unknown. This matters most for people with diabetes on glucose-lowering drugs.
- Kidneys. Chaga is very high in oxalate; case reports describe kidney failure from oxalate deposits after months to years of daily chaga powder (see the MSKCC section above).
- Source. Wild-harvested birch chaga differs from cultivated material and from unverified products; MSKCC notes that natural reserves of the fungus have nearly been exhausted and that scientists are seeking to develop cultivated substitutes.
Key Research Papers
- Pisha E, Chai H, Lee IS, et al. (1995). Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nature Medicine 1(10):1046-1051. — PubMed PMID: 7489361
- Fulda S (2008). Betulinic acid for cancer treatment and prevention. International Journal of Molecular Sciences 9(6):1096-1107. — PubMed PMID: 19325847
- Fulda S, Friesen C, Los M, et al. (1997). Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Research 57(21):4956-4964. — PubMed PMID: 9354463
- Lemieszek MK, Langner E, Kaczor J, et al. (2011). Anticancer effects of fraction isolated from fruiting bodies of chaga medicinal mushroom, Inonotus obliquus: in vitro studies. International Journal of Medicinal Mushrooms 13(2):131-143. — cell culture only; this paper contains no animal data. — PubMed PMID: 22135889
- Burczyk J, Gawron A, Slotwinska M, et al. (1996). Antimitotic activity of aqueous extracts of Inonotus obliquus. Bollettino Chimico Farmaceutico 135(5):306-309. — HeLa S3 cervical cancer cells in culture. — PubMed PMID: 8942059
- Youn MJ, Kim JK, Park SY, et al. (2009). Potential anticancer properties of the water extract of Inonotus obliquus by induction of apoptosis in melanoma B16-F10 cells. Journal of Ethnopharmacology 121(2):221-228. — PubMed PMID: 19041933
- Youn MJ, Kim JK, Park SY, et al. (2008). Chaga mushroom (Inonotus obliquus) induces G0/G1 arrest and apoptosis in human hepatoma HepG2 cells. World Journal of Gastroenterology 14(4):511-517. — PubMed PMID: 18203281
- Lee SH, Hwang HS, Yun JW (2009). Antitumor activity of water extract of a mushroom, Inonotus obliquus, against HT-29 human colon cancer cells. Phytotherapy Research 23(12):1784-1789. — PubMed PMID: 19367670
- Fan L, Ding S, Ai L, Deng K (2012). Antitumor and immunomodulatory activity of water-soluble polysaccharide from Inonotus obliquus. Carbohydrate Polymers 90(2):870-874. — PubMed PMID: 22840014
- Sun JE, Ao ZH, Lu ZM, et al. (2008). Antihyperglycemic and antilipidperoxidative effects of dry matter of culture broth of Inonotus obliquus in submerged culture on normal and alloxan-diabetes mice. Journal of Ethnopharmacology 118(1):7-13. — a glucose and lipid-peroxidation study; it reports no tumor endpoint — PubMed PMID: 18434051
- Arata S, Watanabe J, Maeda M, et al. (2016). Continuous intake of the chaga mushroom (Inonotus obliquus) aqueous extract suppresses cancer progression and maintains body temperature in mice. Heliyon 2(5):e00111. — an animal study, not a human one. — PubMed PMID: 27441282
- Najafzadeh M, Reynolds PD, Baumgartner A, et al. (2007). Chaga mushroom extract inhibits oxidative DNA damage in lymphocytes of patients with inflammatory bowel disease. BioFactors 31(3-4):191-200. — PubMed PMID: 18997282
- Zhao Y, Zheng W (2021). Deciphering the antitumoral potential of the bioactive metabolites from medicinal mushroom Inonotus obliquus. Journal of Ethnopharmacology 265:113321. — PubMed PMID: 32877719
- Miyake Y, Nishimura J, Kato T, et al. (2018). Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG). Surgery Today 48(1):66-72. — the PSK arm failed to show non-inferiority. — PubMed PMID: 28634730
- Ogawa H, Shiraishi T, Okada T, et al. (2024). Adjuvant chemotherapy with UFT/LV versus UFT/LV plus PSK in stage II/III colorectal cancer. Anticancer Research 44(2):805-814. — no significant difference in 3-year disease-free survival. — PubMed PMID: 38307591
- Nakazato H, Koike A, Saji S, et al. (1994). Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343(8906):1122-1126. — PubMed PMID: 7910230
- Ohwada S, Ikeya T, Yokomori T, et al. (2004). Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. British Journal of Cancer 90(5):1003-1010. — PubMed PMID: 14997197
- Sakamoto J, Morita S, Oba K, et al. (2006). Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunology, Immunotherapy 55(4):404-411. — PubMed PMID: 16133112
- Kikuchi Y, Seta K, Ogawa Y, et al. (2014). Chaga mushroom-induced oxalate nephropathy. Clinical Nephrology 81(6):440-444. — PubMed PMID: 23149251
- Lee S, Lee HY, Park Y, et al. (2020). Development of end stage renal disease after long-term ingestion of chaga mushroom: case report and review of literature. Journal of Korean Medical Science 35(19):e122. — PubMed PMID: 32419395
- Smith PF, Ogundele A, Forrest A, et al. (2007). Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 51(10):3574-3581. — PubMed PMID: 17638699
PubMed Topic Searches
- PubMed: Inonotus obliquus chaga cancer antitumor
- PubMed: Betulinic acid apoptosis tumor cell
- PubMed: Chaga gastric cancer Russian folk medicine
- PubMed: Medicinal mushroom adjuvant chemotherapy cancer survival
- PubMed: Betulinic acid intravenous phase I trials
- PubMed: Mushroom polysaccharide NK / anti-tumor immunity